commande venlafaxine prix clomid nizoral prix lamisil vente lioresal vente propecia prix pharmacie acheter pentasa en ligne
  • generic propecia online genertic viagra generic for celebrex augmentin allergic reactions interactio norvasc amoxicillin appropriate dose of bactrim zithromax antibiotic over the counter
  • viagr en ligne viagra online ohne rezept cialis generika schweiz cialis vendita farmacia cialis testen vendo viagra santiago kamagra envío rápido de toda europa
  • buy cheap champix online no prescription fast delivery cipro heartburn birth control pill alesse propecia online prescription viagra without prescription. albendazole mg buy levitra without prescription viagra orgasm viagra steroids
    nolvadex pharmacie allegra comprar en línea
    acheter viagra authentique echte kamagra acheter priligy
    viagra original oder generika 
    viagra online kaufen erfahrungen 
    cialis 5 mg preis 

    Certain head and neck cancer patients benefit from second round of treatment

    Mon, Jun 13, 2011

    Oral Cancer News

    Author: press release

    A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings could help guide treatment decisions for head and neck cancer patients.

    Radiation is often used to treat patients with head and neck cancer. If their cancer reappears, they have limited treatment choices: chemotherapy is not curative, and surgery can be curative but is often not possible. Chemotherapy and a second course of radiation have previously been shown to be another option. Joseph Salama, MD, formerly of the University of Chicago, and his colleagues conducted an analysis of prior studies to determine how patients tolerate this second round of treatment and which patients benefit the most from it.

    The investigators analyzed data from 166 patients with head and neck cancer who received a first round of radiation followed by a second round plus chemotherapy because their cancer recurred or they developed a new tumor. The second course of treatment could cure approximately 25 percent of patients at two years, but it was quite toxic. (Some patients lost the ability to speak or swallow. In addition, approximately 20 percent of patients died from treatment-related complications.)

    Certain patients benefited from the treatment over others. Those who were cancer-free for a longer period of time, did not have chemotherapy with their first course of radiation, were treated with a higher dose of radiation in the second round, and had surgery prior to the second course of radiation were more likely to be cured at two years than those who had none or only one of these features. “These can help doctors determine which patients are best suited for a second course of radiation with chemotherapy for head and neck cancer,” said Dr. Salama.

    The authors concluded that for patients with recurrent head and neck cancer in a previously irradiated area, concomitant chemotherapy with reirradiation is a treatment option that offers a small but real chance of cure in select patients; however, due to the risk of severe toxicity, the treatment should be limited to investigational studies and experienced medical centers.

    Print Friendly
    Be Sociable, Share!
    , , , , ,

    Leave a Reply

    You must be logged in to post a comment.